What question did this study set out to answer?

This study aims to describe the outcomes of elderly patients with diffuse large B-cell lymphoma and high-grade B-cell lymphoma treated in first-line therapy.

December 8, 2025BloodOpen Access

Outcomes of diffuse large B-cell lymphoma and high-grade B-cell lymphoma in elderly patients aged ≥ 80 years-old treated in first line therapy: An analysis of the bra-DLBCL multicenter, real-world registry, retrospective study

View Full Paper

Ask AI

Bookmark

Authors

CFCarolina FeresHospital Israelita Albert Einstein LTLarissa Lane Cardoso TeixeiraHospital Israelita Albert Einstein TSTalita SilveiraAC Camargo Hospital

Discussion

Member takes

Implication

Multicenter analysis shows progression-free survival in elderly patients with lymphoma, suggesting real-world treatment implications.

Key Points

This study aims to describe the outcomes of elderly patients with diffuse large B-cell lymphoma and high-grade B-cell lymphoma treated in first-line therapy.
Retrospective observational analysis of patients registered in a Brazilian multicenter study.
Focus on real-world data in patients aged 80 years or older diagnosed with DLBCL and HGBL.
Assessment of progression-free survival and overall survival with Kaplan-Meier and cumulative incidence curves.
76 patients included with a median age of 87 years.
3-year progression-free survival rate was 39%, and overall survival was 45%.
Non-relapse mortality rate was high at 26%, indicating challenges in elderly care.

Cite This Study

Feres et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0c4 https://doi.org/10.1182/blood-2025-8070

View Full Paper

Ask AI

Bookmark

Outcomes of diffuse large B-cell lymphoma and high-grade B-cell lymphoma in elderly patients aged ≥ 80 years-old treated in first line therapy: An analysis of the bra-DLBCL multicenter, real-world registry, retrospective study

Discussion

Member takes

Implication

Key Points

Cite This Study

Outcomes of diffuse large B-cell lymphoma and high-grade B-cell lymphoma in elderly patients aged ≥ 80 years-old treated in first line therapy: An analysis of the bra-DLBCL multicenter, real-world registry, retrospective study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider